Moleculin Reports Full Year Financial Results and Provides Programs Update
- Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine - - Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute Myeloid Leukemia (AML)...
Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
HOUSTON, March 23, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference
Presentation with live webcast on Thursday, March 17th at 9:20 AM ETHOUSTON, March 11, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors
- Biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with successful track record leading development of multiple oncology products from strategic planning through global submissions and...
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
- Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine- Phase 1 study sets a recommended Phase 2 dose of 240 mg/m², enabling start of combination trial-...
Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference
- Live video webcast presentation on Thursday, January 27th at 9:00 AM ET -HOUSTON, Jan. 20, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma
- Review of preliminary interim data continues to demonstrate the absence of cardiotoxicity for Annamycin, representing a significant advancement in patient safety- Preliminary interim data for Annamycin shows a reduced rate of alopecia compared to currently approved...
Moleculin to Present at the H.C. Wainwright BioConnect Conference
HOUSTON, Jan. 7, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
- Preliminary data currently demonstrate 50% of patients in first two cohorts experienced clinical activity, defined as stable disease and/or better through 4 months or more of treatment- Patient enrollment and dosing ongoing; no dose-limiting toxicity (DLT)...